01:05 AM EST, 11/12/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Our 12-month target price of $206, raised by $1, reflects a 13.8x multiple of projected EPS over the next 12 months. The applied multiple is based on a 20% discount to key MedTech rivals Medtronic, Abbott Laboratories, and Stryker Corporation, and we think a discount is merited by BDX's relatively smaller size as well as BDX guidance for FY 26 (Sep.) that is, in our view, somewhat underwhelming (both revenues and EPS in the low single digits) vs. peers in the high single digits. Previously, we had applied a multiple based on BDX's historical forward average, but we now see that approach as inadequate given the pending spin-off of much of the company's Life Sciences segment. We lift our FY 26 EPS estimate by $0.10 to $14.90, and start FY 27's at $15.75. BDX is working on margin enhancement and medtech innovations that clients can scale and use easily, but anticipated margin pressure from tariffs is likely to offset these gains in FY 26. Shares also yield 2.2%.